Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications. Jonathan Dowell, MD, explores the significance of molecular alterations and ROS1 rearrangements in NSCLC. He also delves into the nuances and considerations of different targeted treatment options, patient characteristics, safety profiles of targeted therapies, and sequencing considerations to personalize treatment.
The didactic portion of this activity is also available as a podcast. You may listen here.
Course Credit:
0.75 AAPA Category I Hours
0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
Dates:
Opens: 2024-09-30
Closes: 2025-09-30
Target Audience:
This activity was developed for oncologists, pathologists, oncology nurse practitioners, nurses, physician associates, pharmacists, and other healthcare professionals involved in the care of patients diagnosed with non-small cell lung cancer (NSCLC).
This activity is supported by an educational grant from Bristol Myers Squibb.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Jada Dillner, PA (Peer Reviewer)No significant relationships to disclose.
Chris Elder, PharmD, BCOP (Medical Writer)
Advisory Board: Bristol Myers Squibb, Genentech, Janssen, Novartis, Pfizer, Pharmacosmos
Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Jonathan Dowell, MD
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Presenting Faculty
Downloads
Learning Objectives
- Evaluate current first-line treatment options in patients with ROS1 rearranged NSCLC
- Optimize ROS1 targeted tyrosine kinase inhibitors in individual patients consistent with current evidence-based guideline recommendations
- Assess recent clinical data for emerging therapies in ROS1 rearranged NSCLC
Faculty Disclosures
Jonathan Dowell, MD
Advisory Board: Catalyst, Regeneron, Takeda